Quince Therapeutics (QNCX) Competitors

$1.22 -0.03 (-2.02%)

As of 02:58 PM Eastern

QNCX vs. BTMD, JATT, CTOR, LONA, and EXOZ

Should you buy Quince Therapeutics stock or one of its competitors? MarketBeat compares Quince Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quince Therapeutics include biote (BTMD), JATT Acquisition (JATT), Citius Oncology (CTOR), Athira Pharma (LONA), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.

How does Quince Therapeutics compare to biote?

biote (NASDAQ:BTMD) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

biote has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

biote currently has a consensus target price of $2.75, suggesting a potential upside of 24.38%. Quince Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 5,249.79%. Given Quince Therapeutics' higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

biote has a net margin of 8.29% compared to Quince Therapeutics' net margin of 0.00%. biote's return on equity of -24.04% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-24.04%	14.46%
Quince Therapeutics	N/A	-372.88%	-62.36%

21.7% of biote shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, biote had 5 more articles in the media than Quince Therapeutics. MarketBeat recorded 8 mentions for biote and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.62 beat biote's score of -0.12 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

biote has higher revenue and earnings than Quince Therapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.45	$27.05M	$0.44	5.03
Quince Therapeutics	N/A	N/A	-$83.98M	-$16.90	N/A

Summary

biote beats Quince Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to JATT Acquisition?

Quince Therapeutics (NASDAQ:QNCX) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$16.90	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Quince Therapeutics currently has a consensus price target of $65.00, indicating a potential upside of 5,249.79%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Quince Therapeutics had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Quince Therapeutics and 0 mentions for JATT Acquisition. Quince Therapeutics' average media sentiment score of 1.62 beat JATT Acquisition's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Very Positive
JATT Acquisition	Neutral

JATT Acquisition's return on equity of -49.58% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-62.36%
JATT Acquisition	N/A	-49.58%	2.84%

Summary

JATT Acquisition beats Quince Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Quince Therapeutics compare to Citius Oncology?

Quince Therapeutics (NASDAQ:QNCX) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Citius Oncology has higher revenue and earnings than Quince Therapeutics. Citius Oncology is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$16.90	N/A
Citius Oncology	$3.94M	19.76	-$24.76M	-$0.31	N/A

Quince Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.56, meaning that its share price is 256% more volatile than the broader market.

Citius Oncology's return on equity of -55.19% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-62.36%
Citius Oncology	N/A	-55.19%	-23.99%

Quince Therapeutics presently has a consensus target price of $65.00, suggesting a potential upside of 5,249.79%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 579.50%. Given Quince Therapeutics' higher possible upside, equities analysts clearly believe Quince Therapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Quince Therapeutics and Quince Therapeutics both had 3 articles in the media. Quince Therapeutics' average media sentiment score of 1.62 beat Citius Oncology's score of 0.79 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Citius Oncology beats Quince Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Quince Therapeutics compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Athira Pharma has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Quince Therapeutics' return on equity of -372.88% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Quince Therapeutics	N/A	-372.88%	-62.36%

In the previous week, Athira Pharma had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 5 mentions for Athira Pharma and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.62 beat Athira Pharma's score of 0.74 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 25.1% of Athira Pharma shares are owned by insiders. Comparatively, 16.8% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Athira Pharma is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.78	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$16.90	N/A

Athira Pharma currently has a consensus price target of $10.00, indicating a potential downside of 2.21%. Quince Therapeutics has a consensus price target of $65.00, indicating a potential upside of 5,249.79%. Given Quince Therapeutics' higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Athira Pharma beats Quince Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Quince Therapeutics compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

eXoZymes' return on equity of -147.18% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-147.18%	-104.98%
Quince Therapeutics	N/A	-372.88%	-62.36%

30.8% of Quince Therapeutics shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 16.8% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

eXoZymes has higher revenue and earnings than Quince Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	1,198.10	-$9.16M	-$1.08	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$16.90	N/A

In the previous week, Quince Therapeutics had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Quince Therapeutics and 2 mentions for eXoZymes. Quince Therapeutics' average media sentiment score of 1.62 beat eXoZymes' score of 0.62 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Quince Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 5,249.79%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

eXoZymes has a beta of 2.85, meaning that its stock price is 185% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Summary

Quince Therapeutics beats eXoZymes on 7 of the 13 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.80M	$3.41B	$6.28B	$12.10B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-0.07	15.30	20.55	25.41
Price / Sales	N/A	303.37	545.88	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	-0.19	6.85	9.62	6.65
Net Income	-$83.98M	$24.11M	$3.55B	$333.40M
7 Day Performance	-1.22%	-1.57%	-0.36%	-0.58%
1 Month Performance	-10.86%	3.83%	5.99%	7.66%
1 Year Performance	-88.20%	71.34%	38.59%	35.36%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	2.823 of 5 stars	$1.22 -2.0%	$65.00 +5,249.8%	-87.8%	$19.80M	N/A	N/A	60	Positive News Upcoming Earnings Analyst Upgrade
BTMD biote	3.8687 of 5 stars	$2.11 -3.7%	$2.75 +30.3%	-44.6%	$86.62M	$192.22M	2.81	194	Earnings Report
JATT JATT Acquisition	N/A	$10.75 -1.7%	N/A	+788.5%	$83.85M	N/A	N/A	3
CTOR Citius Oncology	2.6031 of 5 stars	$0.92 -2.6%	$6.00 +552.2%	+2.7%	$83.41M	N/A	N/A	N/A	News Coverage
LONA Athira Pharma	1.8634 of 5 stars	$9.55 +8.3%	$10.00 +4.7%	N/A	$82.85M	N/A	N/A	40	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. BTMD, JATT, CTOR, LONA, and EXOZ

How does Quince Therapeutics compare to biote?

Summary

How does Quince Therapeutics compare to JATT Acquisition?

Summary

How does Quince Therapeutics compare to Citius Oncology?

Summary

How does Quince Therapeutics compare to Athira Pharma?

Summary

How does Quince Therapeutics compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. BTMD, JATT, CTOR, LONA, and EXOZ

How does Quince Therapeutics compare to biote?

Which has more volatility and risk, BTMD or QNCX?

Do analysts recommend BTMD or QNCX?

Is BTMD or QNCX more profitable?

Do institutionals and insiders hold more shares of BTMD or QNCX?

Does the media prefer BTMD or QNCX?

Which has stronger earnings & valuation, BTMD or QNCX?

Summary

How does Quince Therapeutics compare to JATT Acquisition?

Which has better earnings and valuation, QNCX or JATT?

Do institutionals & insiders believe in QNCX or JATT?

Do analysts prefer QNCX or JATT?

Does the media refer more to QNCX or JATT?

Is QNCX or JATT more profitable?

Summary

How does Quince Therapeutics compare to Citius Oncology?

Which has stronger valuation and earnings, QNCX or CTOR?

Which has more risk and volatility, QNCX or CTOR?

Is QNCX or CTOR more profitable?

Do analysts recommend QNCX or CTOR?

Does the media prefer QNCX or CTOR?

Do insiders and institutionals hold more shares of QNCX or CTOR?

Summary

How does Quince Therapeutics compare to Athira Pharma?

Which has more risk & volatility, LONA or QNCX?

Is LONA or QNCX more profitable?

Does the media prefer LONA or QNCX?

Do institutionals and insiders have more ownership in LONA or QNCX?

Which has preferable valuation and earnings, LONA or QNCX?

Do analysts prefer LONA or QNCX?

Summary

How does Quince Therapeutics compare to eXoZymes?

Is EXOZ or QNCX more profitable?

Do insiders & institutionals have more ownership in EXOZ or QNCX?

Which has better earnings and valuation, EXOZ or QNCX?

Does the media refer more to EXOZ or QNCX?

Do analysts recommend EXOZ or QNCX?

Which has more volatility and risk, EXOZ or QNCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools